Today's 3 Worst Stocks in the S&P 500

Two health-care companies and one leader in an innovative field of technology end as steep decliners in the stock market today

Jan 6, 2014 at 7:56PM

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Fun fact: the S&P 500 Index (SNPINDEX:^GSPC) has fallen each and every day the stock market has been open for trading in 2014. Thankfully that's not really so ominous, since Wall Street's only seen three days of trading in the nascent year. While the severe winter weather around the U.S. -- currently slowing travel and commerce -- will eventually abate, longer-term questions about the labor market and monetary policy remain as chief concerns for investors looking to the year ahead. But today the horrific weather was the headline as thousands of flights were cancelled and the S&P 500 fell 4 points, or 0.3%, to end at 1,826. 

The absolute worst performer in the 500-stock index, losing nearly a tenth of its value in just six and a half hours, was First Solar (NASDAQ:FSLR), which fell 9.7% Monday. Shareholders can blame Goldman Sachs analyst Brian Lee for the painful portfolio-busting downgrade he gave First Solar today, citing a lack of diversification between the utilities and residential markets. Lee, who also slapped a $45 target price on shares, thinks First Solar's extreme bias toward utilities as end-users is shortsighted. Solar energy is a high-risk, high-reward industry, but with First Solar's revenue surging by 170% between 2008 and 2012, the company isn't exactly in any existential danger.

Playing its role as antagonist like few other investment banks can, a Goldman Sachs downgrade was also the primary reason for Celgene's (NASDAQ:CELG) 4.2% dip today. The $67 billion New Jersey-based biotech was one of several big names in its industry to suffer from Goldman's sweeping biotech sector downgrade Monday. The Wall Street bank feels valuations are, broadly speaking, stretched beyond the point of being attractive. Investors are hoping that Celgene's blockbuster oncology treatment Revlimid, as well as the FDA-approved Pomalyst, will continue to prove doubters wrong in 2014.

Interestingly, AbbVie (NYSE:ABBV), the $80 billion biopharmaceutical company out of Chicago, also finished as a laggard today, losing ground even after one bank boosted its price target on the stock. AbbVie stock shed 3.7% even after UBS raised its target price by $10 to $56 per share, underscoring the fact that while analysts may move markets, they're not the visionaries some hold them to be. While it will be tough to match the 60% gains AbbVie saw in 2013, a portfolio that includes the top-selling drug in the world can't be too shabby.

2 game-changing biotechs revolutionizing the way we treat cancer
Even though the crystal ball of the Wise Ones over at Goldman Sachs foresees an uphill climb for biotechs, we at the Motley Fool still believe it's a corner of the market with a lot of potential. The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that Big Pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Fool contributor John Divine has no position in any stocks mentioned. You can follow him on Twitter, @divinebizkid, and on Motley Fool CAPS, @TMFDivine.

The Motley Fool recommends Celgene and Goldman Sachs. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers